logo

For the Inventor, By the Inventor

Basel, Switzerland

Andreas Kordikowski

This inventor holds 7 USPTO granted patents and 4 published patent applications and 5 EPO patents. Top assignee: Novartis Ag. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andreas Kordikowski. Retrieved from https://idiyas.com/inventor/andreas-kordikowski-t5b6vwu9

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 85.7

 

Average Co-Inventor Count = 4.0

ph-index = 1


Location History:

  • Basel, CH (2018)
  • Binningen, CH (2023 - 2024)

Company Filing History:

goldMedal6 out of 3,978 
 
Novartis Ag
 patents
where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents
1. 12751949 - Crystalline forms of a BTK inhibitor (2026-10-06),
2. 12084460 - Crystalline forms of a TLR7/TLR8 inhibitor (2024-09-10),
3. 11993582 - Crystalline forms of a LTA4H inhibitor (2024-05-28),
4. 11932630 - Heteroaryl aminopropanol derivatives (2024-03-19),
5. 11891401 - Solid forms of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide (2024-02-06),
6. 11597733 - Compounds and compositions for the treatment of parasitic diseases (2023-03-07),
7. 10071973 - Crystalline isoxazole hydroxamic acid compounds (2018-09-11),

Title: The Innovations of Andreas Kordikowski

Introduction

Andreas Kordikowski is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative treatments for autoimmune diseases. With a total of six patents to his name, Kordikowski's work is recognized for its potential impact on healthcare.

Latest Patents

Kordikowski's latest patents include groundbreaking applications related to crystalline forms of a TLR7/TLR8 inhibitor. This application focuses on various crystalline forms of (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide. These materials are particularly useful in treating various autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. Another significant patent involves crystalline forms of a LTA4H inhibitor, which addresses diseases and disorders typically ameliorated by the inhibition of LTA4H, including inflammatory and autoimmune disorders.

Career Highlights

Kordikowski is currently employed at Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative research and development in the pharmaceutical sector. His contributions have been instrumental in advancing treatments that address complex health issues.

Collaborations

Throughout his career, Kordikowski has collaborated with talented individuals such as Siyi Jiang and Yudong Cao. These collaborations have fostered a productive environment for innovation and have led to the successful development of new therapeutic solutions.

Conclusion

Andreas Kordikowski's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and collaborations highlight his commitment to improving healthcare through scientific advancements. His contributions are paving the way for new treatments that can significantly enhance the quality of life for patients suffering from autoimmune diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…